662 related articles for article (PubMed ID: 26331539)
1. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
Prost S; Relouzat F; Spentchian M; Ouzegdouh Y; Saliba J; Massonnet G; Beressi JP; Verhoeyen E; Raggueneau V; Maneglier B; Castaigne S; Chomienne C; Chrétien S; Rousselot P; Leboulch P
Nature; 2015 Sep; 525(7569):380-3. PubMed ID: 26331539
[TBL] [Abstract][Full Text] [Related]
2. PPARγ: Welcoming the New Kid on the CML Stem Cell Block.
Apsel Winger B; Shah NP
Cancer Cell; 2015 Oct; 28(4):409-411. PubMed ID: 26461088
[TBL] [Abstract][Full Text] [Related]
3. PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells.
Glodkowska-Mrowka E; Manda-Handzlik A; Stelmaszczyk-Emmel A; Seferynska I; Stoklosa T; Przybylski J; Mrowka P
Blood Cancer J; 2016 Jan; 6(1):e377. PubMed ID: 26745851
[No Abstract] [Full Text] [Related]
4. Haematological cancer: Repositioned to attack CML cells.
Killock D
Nat Rev Clin Oncol; 2015 Nov; 12(11):624. PubMed ID: 26391777
[No Abstract] [Full Text] [Related]
5. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
Chen M; Gallipoli P; DeGeer D; Sloma I; Forrest DL; Chan M; Lai D; Jorgensen H; Ringrose A; Wang HM; Lambie K; Nakamoto H; Saw KM; Turhan A; Arlinghaus R; Paul J; Stobo J; Barnett MJ; Eaves A; Eaves CJ; Holyoake TL; Jiang X
J Natl Cancer Inst; 2013 Mar; 105(6):405-23. PubMed ID: 23446755
[TBL] [Abstract][Full Text] [Related]
6. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
Lin H; Chen M; Rothe K; Lorenzi MV; Woolfson A; Jiang X
Oncotarget; 2014 Sep; 5(18):8637-50. PubMed ID: 25226617
[TBL] [Abstract][Full Text] [Related]
7. Cancer: Repositioned to kill stem cells.
Holyoake T; Vetrie D
Nature; 2015 Sep; 525(7569):328-9. PubMed ID: 26331538
[No Abstract] [Full Text] [Related]
8. The implication of cancer progenitor cells and the role of epigenetics in the development of novel therapeutic strategies for chronic myeloid leukemia.
Tortorella SM; Hung A; Karagiannis TC
Antioxid Redox Signal; 2015 Jun; 22(16):1425-62. PubMed ID: 25366930
[TBL] [Abstract][Full Text] [Related]
9. Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG; Holyoake TL
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
[TBL] [Abstract][Full Text] [Related]
10. Suppression of autophagy by BCR/ABL.
Calabretta B; Salomoni P
Front Biosci (Schol Ed); 2012 Jan; 4(2):453-60. PubMed ID: 22202070
[TBL] [Abstract][Full Text] [Related]
11. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?
Goldman J; Gordon M
Leuk Lymphoma; 2006 Jan; 47(1):1-7. PubMed ID: 16321820
[TBL] [Abstract][Full Text] [Related]
12. [Tyrosine kinase inhibitors for the treatment of CML].
Heim D
Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
[TBL] [Abstract][Full Text] [Related]
13. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
Ng KP; Manjeri A; Lee KL; Huang W; Tan SY; Chuah CT; Poellinger L; Ong ST
Blood; 2014 May; 123(21):3316-26. PubMed ID: 24705490
[TBL] [Abstract][Full Text] [Related]
14. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
15. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
Corbin AS; Agarwal A; Loriaux M; Cortes J; Deininger MW; Druker BJ
J Clin Invest; 2011 Jan; 121(1):396-409. PubMed ID: 21157039
[TBL] [Abstract][Full Text] [Related]
16. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
[TBL] [Abstract][Full Text] [Related]
17. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
[TBL] [Abstract][Full Text] [Related]
18. Dual PPARalpha/gamma ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines.
Zang C; Liu H; Waechter M; Eucker J; Bertz J; Possinger K; Koeffler HP; Elstner E
Cell Cycle; 2006 Oct; 5(19):2237-43. PubMed ID: 17102607
[TBL] [Abstract][Full Text] [Related]
19. [Research advance on molecular genetics of CML blast crisis].
Zhu HQ; Zhang S; Liu XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK
Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
